Strikingly, 5.00% (2/40) of advanced melanomas exhibited upregulated AKT2-206 expression in the absence of established resistance drivers, suggesting that it may serve as an independent resistance mechanism in molecularly distinct patient subgroups. The gene discussed is AKT2; the disease is melanoma.